U.S. District Court blocks Mylan's generic antibiotic

Mylan launch stopped pending court decision

DUBLIN — A federal court in New Jersey has blocked an attempt by Mylan to market a generic version of a drug made by Warner Chilcott.

Warner Chilcott announced Thursday that the U.S. District Court for the District of New Jersey granted its motion for a preliminary injunction against Mylan to prevent it from launching a generic version of the antibiotic Doryx (doxycycline) in the 150-mg strength until the court makes a decision relating to a patent covering the drug, which Warner Chilcott and Mayne Pharmaceuticals allege Mylan to have infringed.

According to IMS Health, Doryx in the 150-mg strength represents more than 95% of Warner Chilcott's entire Doryx franchise based on total prescriptions.

Login or Register to post a comment.